Immunocore Holdings (IMCR) is back in focus after reporting Q1 2026 results, with revenue of US$106.68 million, net income of US$12.97 million, and diluted EPS of US$0.25 from continuing operations.

The Q1 2026 update arrived alongside a sharp 1 day share price return of 6.55% and a 7 day share price return of 10.06%. However, the year to date share price return of negative 9.03% and 3 year total shareholder return of negative 48.66% show that momentum has weakened over a longer horizon.

If Immunocore’s earnings news has you thinking more broadly about healthcare opportunities, this could be a good moment to scan for other promising healthcare AI stocks using the 32 healthcare AI stocks.

With profits now positive and the stock still down over the year to date, Immunocore sits in an interesting spot. Is the market overlooking its progress, or already pricing in everything from KIMMTRAK and the broader pipeline?

Most Popular Narrative: 54% Undervalued

The most followed narrative puts Immunocore’s fair value at $66.57 versus a last close of $30.73, framing the stock as heavily undervalued on discounted cash flow assumptions.

Significant cash balance ($883 million) and disciplined SG&A spend provide Immunocore with the resources and strategic flexibility to advance its clinical portfolio and capitalize on long-term industry trends, supporting revenue growth and potential positive net margins in the future.

Want to see what sits behind that fair value gap? The narrative leans on compounding revenue, shifting margins, and a hefty future earnings multiple. The exact mix may surprise you.

Result: Fair Value of $66.57 (UNDERVALUED)

However, this hinges on KIMMTRAK staying resilient and late stage trials delivering. At the same time, rising R&D spend and pricing pressure could quickly challenge that optimistic setup.

Next Steps

With both risks and rewards on the table, does the overall mood here feel cautious or quietly optimistic to you? Act while the details are fresh and weigh the upside against the concerns by reviewing the 4 key rewards and 1 important warning sign

Ready to uncover more investment ideas?

Immunocore might be on your radar now, but some of the most interesting opportunities often sit just outside the spotlight, so do not let them pass you by.

• Target companies that combine quality and pricing gaps by scanning our list of 44 high quality undervalued stocks that may warrant a closer look.
• Prioritize resilience in your portfolio by checking out 74 resilient stocks with low risk scores designed for investors who care about steadier risk profiles.
• Spot potential future standouts early by reviewing the screener containing 23 high quality undiscovered gems that many investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.